Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Invitrogen™ PODXL2 Monoclonal Antibody (211816)
GREENER_CHOICE

Mouse Monoclonal Antibody

Supplier:  Invitrogen™ MA523932

Catalog No. PIMA523932


Only null left
Add to Cart

Description

Description

Reconstitute at 0.5 mg/mL in sterile PBS.

Podolyxin is a CD34 family member expressed by podocytes, vascular endothelium, mesothelium, and a subset of hematopoietic progenitors. It is the major sialoprotein in the glycocalyx of glomerular podocytes. The physiologic role of podolyxin in leukemic blasts is unknown. However, it is thought of as a candidate prostate cancer tumor aggressiveness gene. Podolyxin appears to complement CD34 as a useful cell surface marker for hemangioblasts, the common precursors of hematopoietic and endothelial cells.
TRUSTED_SUSTAINABILITY
Specifications

Specifications

PODXL2
Monoclonal
0.5 mg/mL
PBS with 5% trehalose and No Preservative
Q9NZ53
PODXL2
Mouse myeloma cell line NS0-derived recombinant human Endoglycan/PODXL2 Gly33-Thr500.
100 μg
Primary
Human
Antibody
IgG2a
Flow Cytometry, Immunocytochemistry
211816
Unconjugated
PODXL2
D130074J02Rik; EG; endoglycan; LOW QUALITY PROTEIN: podocalyxin-like protein 2; PODLX2; podocalyxin like 2; podocalyxin-like 2; podocalyxin-like protein 2; Podxl2; RGD1305815; sialomucin protein; UNQ1861/PRO3742
Mouse
Protein A/G
RUO
50512
-20°C, Avoid Freeze/Thaw Cycles
Lyophilized
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Product Certifications
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.